Validation of the Point-EXACCT method in non-small cell lung carcinomas

Clin Chem. 1998 Jul;44(7):1404-9.

Abstract

K-ras point mutations are often detected in part of the lung carcinomas. For the validation of a highly sensitive and rapid assay for known point mutations, Point-EXACCT (Biochim Biophys Acta 1998; 1379:42-52), we analyzed 89 non-small cell lung carcinomas and compared the results with two sequencing methods. No point mutations were found with double-stranded sequencing. Single-stranded sequencing detected six patients positive for K-ras codon 12. When Point-EXACCT was used, K-ras codon 12 mutations were detected in 8 of 52 patients with squamous cell carcinomas, 10 of 29 patients with adenocarcinomas, and 3 of 8 patients with large cell carcinomas. The finding of K-ras mutations in squamous cell carcinomas is explained by the high sensitivity of the method. Therefore, Point-EXACCT may be applicable to detection of those alterations occurring at a low frequency among an excess of cells with wild-type DNA.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / genetics*
  • DNA Mutational Analysis / methods
  • DNA, Neoplasm / genetics
  • Female
  • Genes, ras*
  • Humans
  • Lung Neoplasms / genetics*
  • Male
  • Nucleic Acid Amplification Techniques
  • Point Mutation*
  • Reproducibility of Results
  • Sensitivity and Specificity

Substances

  • DNA, Neoplasm